In accordance
with 5 CFR 1320, the information collection is not approved at this
time. Prior to publication of the final rule, the agency should
provide to OMB a summary of all comments received on the proposed
information collection and identify any changes made in response to
these comments.
Inventory as of this Action
Requested
Previously Approved
36 Months From Approved
0
0
0
0
0
0
0
0
0
FDA's legal authority to modify and
simplify the manner in which certain information is presented in
over-the-counter (OTC) drug product labeling derives from sections
201, 502, 503, 505, and 701 of the Federal Food, Drug, and
Cosmetics Act (the act). Regulating the order, appearance, and
format of OTC drug product labeling is consistent with FDA's
authority to ensure that drug labeling conveys all material
information to the consumer (sections 201(n) and 502(a) of the
act), and that labeling communicates this information in a manner
that is ''likely to be read and understood by the ordinary
individual under customary conditions of purchase and use''
(section 502(c) of the act).
This is a new proposed rule,
the burden for the broad spectrum average burden per disclosure is
.5 in the supporting statement but will round to 1 in the
ICRAS/ROCIS system.
$0
No
No
No
No
No
Uncollected
Eliazabeth Berbakos
3018271482
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.